Xie, Ling
Sheehy, Ryan N. https://orcid.org/0000-0001-8212-5357
Muneer, Adil https://orcid.org/0000-0002-8605-3351
Xiong, Yan https://orcid.org/0000-0002-3862-3663
Wrobel, John A. https://orcid.org/0000-0002-5828-9359
Zhang, Feng https://orcid.org/0000-0003-2887-8184
Park, Kwang-Su https://orcid.org/0000-0002-1910-3937
Velez, Julia
Liu, Jing https://orcid.org/0000-0003-4740-243X
Luo, Yan-Jia
Asrican, Brent https://orcid.org/0000-0003-3434-9852
Dong, Ping https://orcid.org/0000-0002-6640-6607
Li, Ya-Dong https://orcid.org/0000-0002-5977-8760
Damian, Corina
Quintanilla, Luis
Li, Yongyi https://orcid.org/0009-0009-1001-3095
Xu, Chongchong
Deshmukh, Mohanish https://orcid.org/0000-0002-2597-5862
Coleman, Leon G. Jr. https://orcid.org/0000-0003-1693-3799
Ming, Guo-Li https://orcid.org/0000-0002-2517-6075
Song, Hongjun https://orcid.org/0000-0002-8720-5310
Wen, Zhexing https://orcid.org/0000-0002-1518-3845
Jin, Jian https://orcid.org/0000-0002-2387-3862
Song, Juan https://orcid.org/0000-0002-7836-343X
Chen, Xian https://orcid.org/0000-0002-8358-1247
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R21AG071229, 1R41AG085859-01, 1R41DK133051-01A1)
Article History
Received: 6 November 2023
Accepted: 9 April 2025
First Online: 7 May 2025
Competing interests
: X.C. is the Founder of Transchromix, LLC. J.J. is a cofounder and equity shareholder in Cullgen, Inc., a scientific cofounder and scientific advisory board member of Onsero Therapeutics, Inc., and a consultant for Cullgen, Inc., EpiCypher, Inc., Accent Therapeutics, Inc, and Tavotek Biotherapeutics, Inc. The Jin laboratory received research funds from Celgene Corporation, Levo Therapeutics, Inc., Cullgen, Inc. and Cullinan Oncology, Inc. The remaining authors declare no competing interests.